| |
| Please Note - Streaming News is only available to subscribers to the Active Level and above |
|
|
|
Renalytix AI reports positive study results for kidney disease test
StockMarketWire.com
|
Kidney disease diagnostics group Renalytix AI announced that a study had indicated its flagship KidneyIntelX test accurately predicted progression of diabetic kidney disease.
Progression was predicted in a multinational cohort from the CANagliflozin CardioVAScular Assessment Study.
'The clinical outcome data suggests that KidneyIntelX risk assessment could support primary care physicians in making appropriate therapeutic intervention decisions with early-stage DKD patients to effectively delay progression and reduce the risk of adverse events,' the company said.
At 9:13am: (LON:RENX) Renalytix Ai PLC share price was 0p at 436p
Story provided by StockMarketWire.com
|
|
|
|
|
|
